Carter-Wallace, Inc. v. Riverton Laboratories, Inc.

47 F.R.D. 366, 12 Fed. R. Serv. 2d 76, 161 U.S.P.Q. (BNA) 697, 1969 U.S. Dist. LEXIS 13409, 1969 Trade Cas. (CCH) 72,704
CourtDistrict Court, S.D. New York
DecidedFebruary 5, 1969
DocketCiv. A. No. 65-4
StatusPublished
Cited by44 cases

This text of 47 F.R.D. 366 (Carter-Wallace, Inc. v. Riverton Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Carter-Wallace, Inc. v. Riverton Laboratories, Inc., 47 F.R.D. 366, 12 Fed. R. Serv. 2d 76, 161 U.S.P.Q. (BNA) 697, 1969 U.S. Dist. LEXIS 13409, 1969 Trade Cas. (CCH) 72,704 (S.D.N.Y. 1969).

Opinion

CANNELLA, District Judge.

Motion by the plaintiff, pursuant to Rule 12(f) of the Federal Rules of Civil Procedure1 to strike paragraphs 13 through 18 of defendant’s amended answer as insufficient in law, is denied.2

The case at bar 3 is a suit for infringement of United States Patent No. 2,724,720 against the defendant based upon its alleged manufacture and sale of a pharmaceutical compound useful as an anti-convulsant and possessing depressant properties in the central nervous system. The patent was issued to plaintiff upon the application of Frank M. Berger and Bernard J. Ludwig and plaintiff is the owner of said patent. Defendant has conceded its infringement of the patent in question should the Court find the patent to be valid and enforceable.4 The defenses which plaintiff seeks to have stricken relate to allegations concerning the validity of the patent, and its enforceability against this defendant.

The standards applicable on a motion to strike must be considered initially for they define the areas in which the Court may determine any questions of law on the merits. Motions of this type are not favored5 and may only be granted if the insufficiency of the defenses is clearly apparent.6 The standards have been stated in a variety of ways. “A motion to strike a defense will be denied if the defense is sufficient as a matter of law or if it fairly presents a question of law or fact which the court ought to hear.”7, or as the court stated in Budget Dress Corp. v. International Ladies’ Garment Workers’ Union, 25 F.R.D. 506, 508 (S.D.N.Y.1959):

A motion to strike for insufficiency was never intended to furnish an op[368]*368portunity for the determination of disputed and substantial questions of law and is not granted if insufficiency of the defense is not clearly apparent or may better be determined in a hearing on the merits (citations omitted).

It is clear, that if there are either questions of fact or disputed questions of law,8 the motion must be denied.9 For the plaintiff to succeed on this motion, the Court must be convinced that there are no questions of fact, that any questions of law are clear and not in dispute, and that under no set of circumstances could the defenses succeed. In examining the defenses, the Court must accept the matters well pleaded as true10 and should not consider matters contained outside the pleadings.11 These narrow standards are designed to provide a party the opportunity to prove his allegations if there is the possibility that his defense or defenses may succeed after a full hearing on the merits.

The keystone defense which is alleged in the amended answer asserts the invalidity and unenforceability of plaintiff’s patent due to a claimed fraud on the Commissioner of Patents in the procurement of the patent. Paragraph 13 of the amended answer details certain allegations, which will be discussed individually, while paragraph 14 complements it with broad characterizations of fraud serving to explain and frame the material contained in paragraph 13.. Defendant has alleged that the patentees “represented to the Commissioner of Patents alleged beneficial effects [of the compound] based on insufficient and inconclusive tests on animals other than human beings.”12 It further alleges that these representations were false, made with knowledge that they were false, with intent to deceive the Commissioner and were relied upon by the Commissioner in issuing the patent to the patentees.13 If these allegations of deliberate misrepresentations can be proven, the patent would be unenforceable against the defendant. As the Supreme Court stated in Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 172, 176, 86 S.Ct. 347, 350, 15 L.Ed.2d 247 (1965), “Under the decisions of this Court, a person sued for infringement may challenge the validity of the patent on various grounds, including fraudulent procurement.” Clearly, if defendant can prove “fraudulent procurement” of the patent, the invalidity of the patent can be established with resulting unenforceability as against this defendant.14 Since the parties do not agree on either the conclusion that fraud was present, or on the relevant underlying facts, this Court cannot make a determination that the defense of fraud is insufficient as a matter of law. Certainly the question of affirmative misrepresentations cannot be [369]*369decided at this juncture and must be left for a hearing on the merits.15

The other prong of the fraud defense alleges that the patentees failed to provide certain information to the Commissioner of Patents at the time the application for a patent was pending.

Paragraph 13 alleges that the patentees practiced a fraud on the Commissioner of Patents in that knowing that the patented material was intended for use on human beings, the patentees failed to conduct adequate, or any, tests on human beings to ascertain the harmful effects on human beings of the material claimed, and failed to present to the Commissioner of Patents the harmful effects on human beings of the patented material * * *.

Two assertions are contained in the portion of the defense quoted. Initially defendant contends that a fraud was perpetrated by a failure to conduct tests of the compound on human beings, and, secondly, that the “harmful effects” of the patented material were withheld from the Commissioner of Patents.16 While it may be argued that the revelation of any harmful effects of the patented material bears no relation to a determination of the patentability of the material17, nevertheless, if it can be established that a withholding of such information was part of a scheme or plan to defraud the Commissioner of Patents, such evidence would have probative value. Viewed in accordance with the standards which the Court must apply on this type of motion, the allegations of a withholding of acquired information by the patentees must be retained and later determined.

The allegation that the patentees failed to conduct any, or adequate, tests upon human beings prior to submission of the application for the patent, rests upon a different principle.18 In effect, defendant has asserted that the patentees had a duty to perform experimentation upon human beings and that a valid patent could not issue without sufficient testing of this nature. Needless to say, plaintiff vigorously disagrees. For a patent to issue, there must be a showing of the utility of the patented material as well as a statement setting forth “the best mode contemplated by the inventor of carrying out his invention.”19 The question of the sufficiency of tests on animals where the contemplated use is to be for human beings, was presented to the Court of Custom and Patent Appeals in a series of cases.20

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gupta v. Saxena
S.D. New York, 2021
SFF-TIR, LLC v. Stephenson
250 F. Supp. 3d 856 (N.D. Oklahoma, 2017)
Daye v. Community Financial Service Centers, LLC
233 F. Supp. 3d 946 (D. New Mexico, 2017)
United States v. Garcia
221 F. Supp. 3d 1275 (D. New Mexico, 2016)
Federal National Mortgage Ass'n v. Milasinovich
161 F. Supp. 3d 981 (D. New Mexico, 2016)
Dorato ex rel. Wrongful Death Claim of Tillison v. Smith
163 F. Supp. 3d 837 (D. New Mexico, 2015)
Estate of Anderson v. Denny's Inc.
291 F.R.D. 622 (D. New Mexico, 2013)
Lane v. Page
272 F.R.D. 581 (D. New Mexico, 2011)
Wyeth v. King Pharmaceuticals, Inc.
396 F. Supp. 2d 280 (E.D. New York, 2005)
Etienne v. Wal-Mart Stores, Inc.
197 F.R.D. 217 (D. Connecticut, 2000)
Estee Lauder, Inc. v. Fragrance Counter, Inc.
189 F.R.D. 269 (S.D. New York, 1999)
Ali v. New York City Transit Authority
176 F.R.D. 68 (E.D. New York, 1997)
Laser Diode Array, Inc. v. Paradigm Lasers, Inc.
964 F. Supp. 90 (W.D. New York, 1997)
Friends of Santa Fe County v. LAC Minerals, Inc.
892 F. Supp. 1333 (D. New Mexico, 1995)
Antoniou v. Thiokol Corp. Group Long Term Disability Plan
829 F. Supp. 1323 (M.D. Florida, 1993)
Mastrocchio v. Unnamed Supervisor Special Invest. Unit
152 F.R.D. 439 (D. Rhode Island, 1993)
Securities & Exchange Commission v. Toomey
866 F. Supp. 719 (S.D. New York, 1992)
Hoppe v. G.D. Searle & Co.
779 F. Supp. 1413 (S.D. New York, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
47 F.R.D. 366, 12 Fed. R. Serv. 2d 76, 161 U.S.P.Q. (BNA) 697, 1969 U.S. Dist. LEXIS 13409, 1969 Trade Cas. (CCH) 72,704, Counsel Stack Legal Research, https://law.counselstack.com/opinion/carter-wallace-inc-v-riverton-laboratories-inc-nysd-1969.